• Investment banking

Farrell calls Walker naive in QRxPharma battle

QRxPharma chairman Peter Farrell says the embattled pain drug developer has faltered due to the US regulator’s shifted goalposts and that disgruntled shareholder Lang Walker is naive if he thinks he can do better.

• Updated Jun 10, 2014
• Jessica Gardner

• Acrux Limited

Lang Walker pushes for QrXPharma board upheaval

Fresh from a multimillion-dollar loss on his investment in pain drug developer QrXPharma, rich list property developer Lang Walker is trying to eject founder Gary Pace and chairman Peter Farrell.

• Updated May 15, 2014
• Jessica Gardner

• Acrux Limited

Rich list names hurt by cruel April for biotech stocks

In April almost $1 billion was wiped from the combined market value of four well-regarded companies: Acrux, Mesoblast, QrXPharma and Prana Biotechnology, dragging down equally well known names such as Waislitz and Liberman.

• Updated May 5, 2014
• Jessica Gardner

QRx Pharma appoints Edward Rudnic new CEO

QRx Pharma said chief executive John Holaday has resigned and will be succeeded immediately by Edward Rudnic, who has been the company’s chief operating officer since early 2012.

• Updated May 2, 2014

Biotech stocks catching analysts off-guard

When things go wrong at the speculative end of any sector, they go very wrong. Take the recently booming biotechs where the challenge for investors is the outcome is so often binary.

• Updated Apr 25, 2014
• Patrick Commins

QRxPharma drops 80pc after US rejects ‘great drug’

Shares in Australian pharmaceutical firm QRxPharma have plummeted 80 per cent in a major shareholder revolt after the company failed to win US regulatory approval for its painkiller Moxduo.

• Updated Apr 23, 2014
• Bianca Hartge-Hazelman

Investors wait on make or break date for QRxPharma

Investors in pain management drug developer QRxPharma face a nervous wait until May for a decision from the US regulator that could make or break the company.

• Updated Mar 17, 2014
• Jessica Gardner

Politics of opioids slow QRxPharma

After two rejections, pain drug developer QRxPharma has a six-month wait before finding out if its product has won US Food and Drug Administration approval.

• Dec 4, 2013
• Jessica Gardner

• Special Reports

2013 a tough year for small caps

The past 12 months have been a miserable affair for many small caps, with the index now trading at its lowest point since April 2009.

• Updated Jul 1, 2013
• Sally Rose

• Pharmaceuticals

More FDA headaches for QRxPharma

Updated | Biotech QRxPharma’s share price has tumbled after it outlined plans to resubmit its MoxDuo drug application this quarter following meetings with the US Food and Drug Administration.

• Updated Jan 19, 2013
• Carrie LaFrenz

• Pharmaxis Ltd

Pharmaxis breathes a little easier

Phamaxis chief executive Alan Robertson says he might find time to give himself a small pat on the back on Wednesday, when the company’s flagship drug will finally get reimbursed by the Australian government.

• Updated Jul 31, 2012
• Emma Connors

• Street Talk

FDA knocks back QRxPharma

It was supposed to be QRxPharma’s day in the sun - the day the powerful US Food and Drug Administration (FDA) was to approve QRxPharma’s pain management drug MoxDuo.

• Jun 28, 2012
• Sarah Thompson and Anthony Macdonald

• ANZ Bank

Company briefs

Alesco chairman Mark Luby has again urged shareholders to reject DuluxGroup’s $2 a share offer.

• Updated Jun 28, 2012

• Bank of Queensland

Company Briefs

Online employment classifieds leader Seek will increase its debt facility headroom to about $145 million following a $125 million subordinated notes issue announced yesterday.

• Updated Jun 5, 2012

• Acrux Limited

Biotechs making a steady recovery

There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies.

• Updated Feb 8, 2012
• Brendon Lau